<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04747951</url>
  </required_header>
  <id_info>
    <org_study_id>127872</org_study_id>
    <nct_id>NCT04747951</nct_id>
  </id_info>
  <brief_title>Total Neoadjuvant Therapy in Rectal Cancer Treatment</brief_title>
  <official_title>Total Neoadjuvant Therapy in Rectal Cancer Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State Scientific Centre of Coloproctology, Russian Federation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>State Scientific Centre of Coloproctology, Russian Federation</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, controlled, parallel study to determine the efficiency and safety of&#xD;
      total neoadjuvant therapy in rectal cancer treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this randomized, controlled, parallel study we will comparison total neoadjuvant therapy&#xD;
      with standard neoadjuvant therapy in rectal cancer treatment. Complete pathological response&#xD;
      rate will be the primary endpoint in patients, who will undergoing surgery. In cases of&#xD;
      complete clinical response we will provide &quot;watch and wait&quot; approach. Compliance of treatment&#xD;
      and oncologic results will be the second endpoint.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 30, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of complete responses</measure>
    <time_frame>3-6 months</time_frame>
    <description>The rate of pathological or clinical complete responses</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of R0-resections</measure>
    <time_frame>immediately after surgery</time_frame>
    <description>Rate of R0-resections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of compliance with radiotherapy and chemotherapy</measure>
    <time_frame>6-8 months</time_frame>
    <description>Rate of complications III-VI grade of radiotherapy (RTOG) and chemotherapy (NCI-CTC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of intraoperative and postoperative complications</measure>
    <time_frame>0-30 days after surgery</time_frame>
    <description>Frequency and structure of intraoperative and postoperative complications according to the Clavien-Dindo classification</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>total neoadjuvant therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total neoadjuvant therapy consisted chemoradiotherapy with capecitabine and nine weeks of consolidation chemotherapy with XELOX prior to surgery and adjuvant therapy if necessary.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard therapy (neoadjuvant chemoradiotherapy, surgery, adjuvant chemotherapy)</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Concurrent Chemoradiotherapy</intervention_name>
    <description>50Gy in 25 fractions to the primary tumor and to mesorectal, presacral,and internal iliac lymph nodes.&#xD;
Concurrent chemotherapy:&#xD;
Capecitabine 1650 mg/m2/d</description>
    <arm_group_label>standard therapy</arm_group_label>
    <arm_group_label>total neoadjuvant therapy</arm_group_label>
    <other_name>Radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TME</intervention_name>
    <description>Total mesorectal excision</description>
    <arm_group_label>standard therapy</arm_group_label>
    <arm_group_label>total neoadjuvant therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>consolidation chemotherapy</intervention_name>
    <description>Intravenous infusion of oxaliplatin (130 mg/m2 over 2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 3 courses, 3 weeks per course</description>
    <arm_group_label>total neoadjuvant therapy</arm_group_label>
    <other_name>XELOX</other_name>
    <other_name>CAPOX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adjuvant chemotherapy</intervention_name>
    <description>Administration of l-LV (400 mg/m2) and oxaliplatin (85 mg/ m2) by intravenous infusion over 2 h, followed by rapid intravenous infusion (iv) of 5-FU (400 mg/m2) and then slow infusion (civ) of 5-FU (2400 mg/m2 over 46 h), is repeated every 2 weeks for 6-12 cycles</description>
    <arm_group_label>standard therapy</arm_group_label>
    <arm_group_label>total neoadjuvant therapy</arm_group_label>
    <other_name>mFOLFOX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have signed an approved informed consent form for the stud;&#xD;
&#xD;
          -  Histologically confirmed rectal adenocarcinoma low (cT2-4N0-2M0) or mid rectum&#xD;
             (сТ2-T4N1-2M0);&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  rectal cancer recurrence;&#xD;
&#xD;
          -  Primary-multiple tumours of other localizations;&#xD;
&#xD;
          -  pelvis radiotherapy in anamnesis;&#xD;
&#xD;
          -  pregnancy, breastfeeding;&#xD;
&#xD;
          -  distant metastasis;&#xD;
&#xD;
          -  ECOG score 3-4&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evgeny Rybakov, Dr.Med.Sc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of Surgical department of oncoproctology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sergey Sychev, Dr.Med.Sc</last_name>
    <phone>+7 9097845436</phone>
    <email>dr.sychev.si@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>State Scientific Centre of Coloproctology</name>
      <address>
        <city>Moscow</city>
        <zip>123453</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergey Sychev</last_name>
      <phone>+79097845436</phone>
      <phone_ext>+79097845436</phone_ext>
      <email>dr.sychev.si@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <reference>
    <citation>Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg. 2012 Jul;99(7):918-28. doi: 10.1002/bjs.8702. Epub 2012 Feb 23. Review.</citation>
    <PMID>22362002</PMID>
  </reference>
  <reference>
    <citation>Zorcolo L, Rosman AS, Restivo A, Pisano M, Nigri GR, Fancellu A, Melis M. Complete pathologic response after combined modality treatment for rectal cancer and long-term survival: a meta-analysis. Ann Surg Oncol. 2012 Sep;19(9):2822-32. doi: 10.1245/s10434-011-2209-y. Epub 2012 Mar 21.</citation>
    <PMID>22434243</PMID>
  </reference>
  <reference>
    <citation>Rödel C, Martus P, Papadoupolos T, Füzesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R, Wittekind C. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005 Dec 1;23(34):8688-96. Epub 2005 Oct 24.</citation>
    <PMID>16246976</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 5, 2021</study_first_submitted>
  <study_first_submitted_qc>February 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2021</study_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>State Scientific Centre of Coloproctology, Russian Federation</investigator_affiliation>
    <investigator_full_name>Rybakov Evgeny, MD</investigator_full_name>
    <investigator_title>Head of Surgical department of oncoproctology</investigator_title>
  </responsible_party>
  <keyword>rectal cancer</keyword>
  <keyword>total neoadjuvant therapy</keyword>
  <keyword>colorectal disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

